GlaxoSmithKline PLC Director/PDMR Shareholding (8297O)
12 Ottobre 2021 - 2:28PM
UK Regulatory
TIDMGSK
RNS Number : 8297O
GlaxoSmithKline PLC
12 October 2021
GlaxoSmithKline plc (the ' Company ')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
==== =========================================================================================
a) Name Ms E Walmsley
==== ====================================== =================================================
b) Position/status Chief Executive Officer
==== ====================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =========================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== =================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 7 October 2021, on shares
held through the Company's Share Reward
Plan.
==== ====================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================= ===================
GBP13.9389 31
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ==========================
e) Date of the transaction 2021-10-07
==== ====================================== =================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =========================================================================================
a) Name Mr R Connor
==== ====================================== =================================================
b) Position/status President, Vaccines & Global Health
==== ====================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =========================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== =================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 7 October 2021, on shares
held through the Company's Share Reward
Plan.
==== ====================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================= ===================
GBP13.9389 89
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ==========================
e) Date of the transaction 2021-10-07
==== ====================================== =================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== =================================================
1. Details of PDMR/person closely associated
with them ('PCA')
==== =====================================================================
a) Name Ms D Conrad
==== ============================ =======================================
b) Position/status SVP, Human Resources
==== ============================ =======================================
c) Initial notification/ Initial notification
amendment
==== ============================ =======================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
==== =====================================================================
a) Name GlaxoSmithKline plc
==== ============================ =======================================
b) LEI 5493000HZTVUYLO1D793
==== ============================ =======================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
==== =====================================================================
a) Description Ordinary shares of 25 pence each
of the financial ('Ordinary Shares')
instrument
ISIN: GB0009252882
==== ============================ =======================================
b) Nature of Acquisition of Ordinary Shares
the transaction following the re-investment of
dividends paid to shareholders
on 7 October 2021, on shares
held through the Company's Share
Reward Plan.
==== ============================ =======================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ============================ ==================== ==============
GBP13.9389 6
====================================================== ==============
d) Aggregated N/A (single transaction)
information
====
Aggregated
volume Price
=================================================== =====================
e) Date of the 2021-10-07
transaction
==== ============================ =======================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ============================ =======================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ========================================================================================
a) Name Mr J Ford
==== ===================================== =================================================
b) Position/status SVP & General Counsel
==== ===================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ===================================== =================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 7 October 2021, on shares
held through the Company's Share Reward
Plan.
==== ===================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== ========================= ===================
GBP 13.9389 4
==================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================= ==========================
e) Date of the transaction 2021-10-07
==== ===================================== =================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ===================================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =========================================================================================
a) Name Ms S Jackson
==== ====================================== =================================================
b) Position/status SVP, Global Communications and CEO Office
==== ====================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =========================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== =================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 7 October 2021, on shares
held through the Company's Share Reward
Plan.
==== ====================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================= ===================
GBP13.9389 82
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ==========================
e) Date of the transaction 2021-10-07
==== ====================================== =================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =============================================================================================
a) Name Mr D Jackson
==== ====================================== =====================================================
b) Position/status PCA of Ms S Jackson (SVP, Global Communications
and CEO Office)
==== ====================================== =====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== =====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== =====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== =====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== =====================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 7 October 2021, on shares
held through the Company's Share Reward
Plan.
==== ====================================== =====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== =========================== =====================
GBP13.9389 32
======================================================================= =====================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
==================================================================== ============================
e) Date of the transaction 2021-10-07
==== ====================================== =====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== =====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =========================================================================================
a) Name Mr L Miels
==== ====================================== =================================================
b) Position/status Chief Commercial Officer
==== ====================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =========================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== =================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 7 October 2021, on shares
held through the Company's Share Reward
Plan.
==== ====================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================= ===================
GBP13.9389 5
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ==========================
e) Date of the transaction 2021-10-07
==== ====================================== =================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =========================================================================================
a) Name Mr D Redfern
==== ====================================== =================================================
b) Position/status Chief Strategy Officer
==== ====================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =========================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== =================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 7 October 2021, on shares
held through the Company's Share Reward
Plan.
==== ====================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================= ===================
GBP13.9389 100
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ==========================
e) Date of the transaction 2021-10-07
==== ====================================== =================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =========================================================================================
a) Name Mr R Simard
==== ====================================== =================================================
b) Position/status President, Pharmaceuticals Supply Chain
==== ====================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =========================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== =================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 7 October 2021, on shares
held through the Company's Share Reward
Plan.
==== ====================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================= ===================
GBP13.9389 31
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ==========================
e) Date of the transaction 2021-10-07
==== ====================================== =================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== =================================================
1. Details of PDMR/person closely associated
with them ('PCA')
==== =====================================================================
a) Name Mr P Thomson
==== ============================ =======================================
b) Position/status President, Global Affairs
==== ============================ =======================================
c) Initial notification/ Initial notification
amendment
==== ============================ =======================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
==== =====================================================================
a) Name GlaxoSmithKline plc
==== ============================ =======================================
b) LEI 5493000HZTVUYLO1D793
==== ============================ =======================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
==== =====================================================================
a) Description Ordinary shares of 25 pence each
of the financial ('Ordinary Shares')
instrument
ISIN: GB0009252882
==== ============================ =======================================
b) Nature of Acquisition of Ordinary Shares
the transaction following the re-investment of
dividends paid to shareholders
on 7 October 2021, on shares
held through the Company's Share
Reward Plan.
==== ============================ =======================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ============================ ==================== ==============
GBP13.9389 60
====================================================== ==============
d) Aggregated N/A (single transaction)
information
====
Aggregated
volume Price
=================================================== =====================
e) Date of the 2021-10-07
transaction
==== ============================ =======================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ============================ =======================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =========================================================================================
a) Name Ms D Waterhouse
==== ====================================== =================================================
b) Position/status Chief Executive Officer of ViiV Healthcare
==== ====================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =========================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== =================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 7 October 2021, on shares
held through the Company's Share Reward
Plan.
==== ====================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================= ===================
GBP13.9389 80
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ==========================
e) Date of the transaction 2021-10-07
==== ====================================== =================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =========================================================================================
a) Name Ms V Whyte
==== ====================================== =================================================
b) Position/status Company Secretary
==== ====================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =========================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== =================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 7 October 2021, on shares
held through the Company's Share Reward
Plan.
==== ====================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================= ===================
GBP13.9389 74
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ==========================
e) Date of the transaction 2021-10-07
==== ====================================== =================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== =================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHLLLFFFBLLFBQ
(END) Dow Jones Newswires
October 12, 2021 08:28 ET (12:28 GMT)
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Apr 2023 a Apr 2024
